In the original article, there was a mistake in Figure 2B as published [1]. Two images from the same mouse with different luminescence signals were presented.
When we image mice, we usually do it twice at different exposure time to make sure we capture any luminescence signals. All the mouse images presented in the manuscript, and the values of luminescence signals used for quantification, are from the same exposure time. However, the two mouse images highlighted in the PBS group in Figure 2B were indeed from the same mouse that were captured at different exposure times. That is why the luminescence signals of the two are different. That is a manual error when processing a large number of images. The authors have double-checked all of them and replaced the panel with a correct image. Another mistake is also fixed with one other image being swapped between the PBS and ONC201 groups. Nevertheless, these did not affect the quantification in Figure 2C, as the calculation was from values generated from the imaging software, which is independent to the process of putting the images together manually. The corrected Figure 2B appears below:
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. All the authors have checked and agreed with the corrected paper content. The original article has been updated.
Reference
1. Hu, W.; Zhang, L.; Ferri-Borgogno, S.; Kwan, S.-Y.; Lewis, K.E.; Cun, H.T.; Yeung, T.-L.; Soliman, P.T.; Tarapore, R.S.; Allen, J.E.; et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12, 2436.
Wen Hu
1,2,
Li Zhang
1,
Sammy Ferri-Borgogno
1,
Suet-Ying Kwan
3,
Kelsey E. Lewis
4,
Han T. Cun
1,
Tsz-Lun Yeung
1,
Pamela T. Soliman
1,
Rohinton S. Tarapore
5,
Joshua E. Allen
5,
Xinyuan Guan
2,
Karen H. Lu
1,
Samuel C. Mok
1 and
Chi-Lam Au-Yeung
1,*
1Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2State Key Laboratory of Oncology in South China and Collaborative Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China
3Department of Molecular and Cellular Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
4Department of Obstetrics and Gynecology, The University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA
5Oncoceutics Inc., Philadelphia, PA 19104, USA
*Author to whom correspondence should be addressed.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2021. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.